Bank Otkritie first financial company in Russia to harness 32G FC with ADVA FSP 3000
ADVA (FSE: ADV) today announced that Bank Otkritie has deployed its FSP 3000 to enable 32Gbit/s Fibre Channel as well as 40 and 100Gbit/s Ethernet services. One of Russia's largest commercial financial companies, Bank Otkritie is the first bank in the country to leverage Gen 6 Fibre Channel technology. Featuring the ADVA OpenFabric™ OTN cross-connect for enhanced availability, the data center interconnect (DCI) solution delivers a new level of capacity and reliability. Comprehensive, in-service assurance and rapid failure detection capabilities are provided by the ADVA ALM fiber monitoring system. ADVA’s Select partner, the IT solution specialist Zettaline, also played a key role in facilitating the project.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200407005043/en/
ADVA's playing a key role in helping Bank Otkritie transport its mission-critical data (Photo: Business Wire)
“As one of Russia’s leading banks, it’s vital that we provide our customers with continuous access to their mission-critical financial data. That’s why the ADVA FSP 3000 combined with OpenFabric™ and ALM assurance technology is the ideal tool. It ensures comprehensive monitoring and testing for the highest network availability and service reliability,” said Andrey Ivashenko, VP and CIO, Bank Otkritie. “By supporting 32Gbit/s Fibre Channel, this new solution has taken our storage data transport to the next stage. And, with the ADVA FSP 3000 OpenFabric™ aggregating lower-speed services onto high-speed wavelengths, we have the power to efficiently provide the data rates that our individual customers require.”
Built on the ADVA FSP 3000, a uniquely compact and efficient optical transport solution, Bank Otkritie’s new DCI network saves significantly on opex. The infrastructure delivers high-capacity Ethernet and Fibre Channel connectivity while consuming extremely low levels of power, helping Bank Otkritie to hit ambitious energy targets even as traffic continues to grow. Featuring ADVA’s OpenFabric™ OTN cross-connect, the new solution also offers ultimate flexibility, enabling services to be turned up remotely and easily. What’s more, the scalable modular design of the platform protects Bank Otkritie’s investment and empowers the company to plan for further expansion.
“Bank Otkritie’s new network provides a significant boost in terms of capacity and efficiency. With our FSP 3000 technology, it supports the most advanced low-latency Fibre Channel services, enabling the bank to maximize the performance of flash-enhanced storage in its data centers,” commented Andreas Jelinek, senior director, sales, Eastern Europe, Russia and CIS, ADVA. “Robustness and reliability were key to this project. That’s why Bank Otkritie also selected our ALM solution. Specifically engineered to be a simple plug-and-play fiber assurance device, it provides continuous monitoring, enabling operators to know immediately if and where issues arise. This real-time data is key to supervising and assuring dark fiber services. And, in the event of any fiber issues, our FSP 3000 OpenFabric™ automatically discovers new paths, enhancing availability and quality of service.”
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.
ADVA Optical Networking SE, Munich, Germany
t +44 1904 699 358
t +49 89 890 665 854
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Closer Collaboration between the EUIPO and EURid to Benefit SMEs25.5.2020 13:30:00 CEST | Press release
The European Union Intellectual Property Office (EUIPO) and EURid, the domain name registry for the .eu, .ею and .ευ top-level domains, are set to intensify collaboration to support trade mark and domain name applicants and owners, particularly small and medium enterprises (SMEs). This collaboration will support users of the EU IP system, particularly startups, by helping them to obtain trade mark and domain name protection in a joined-up manner, so they can secure their brands from the very beginning of their business journey. At present, EU trade mark applicants are advised whether their trade mark is available as a .eu domain name at the end of the online application process at EUIPO. Applicants and holders can also set up alerts to be informed once a .eu domain name that matches their trade mark is registered. Under a new work programme agreed jointly by the two organisations, the EUIPO and EURid will explore the possibility of implementing a reciprocal process when a .eu domain na
TIP Trailer Services Announces Appointment of New CFO25.5.2020 10:05:00 CEST | Press release
TIP Trailer Services, a portfolio company of I Squared Capital, has appointed Hans van Lierop as Chief Financial Officer and management board member. Hans started as CFO for TIP from Monday, 18th of May 2020 and is based in TIP’s international headquarters in Amsterdam, the Netherlands. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200525005042/en/ Hans van Lierop, appointed CFO of TIP Trailer Services (Photo: Business Wire) “I am looking forward to joining TIP’s senior leadership team and leading its Finance organisation and look forward to contributing to TIPs future success. ” Hans van Lierop commented. Hans van Lierop joins TIP with broad international experience from different industries in Europe and Africa. He has held financial leadership roles in Diageo, Airtel and Massmart Walmart. Most recently, Hans Van Lierop was CFO of Massmart Walmart, a South African retail and wholesale distributor with a turnover of US$ 7
Teva Presented New Data at the European Academy of Neurology Congress Evaluating the AJOVY ® (fremanezumab) Experience in Populations with Difficult-to-Treat Migraine25.5.2020 08:00:00 CEST | Press release
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) presented a wide range of important new data on AJOVY® (fremanezumab) and the societal and economic impact of migraine in Europe at the 6th Congress of the European Academy of Neurology (EAN). This year’s EAN congress was a virtual meeting due to the global coronavirus pandemic. The fremanezumab data included pooled analyses of the AJOVY Phase 3 clinical trials (FOCUS, HALO-episodic migraine (EM) and HALO-chronic migraine (CM)) which focused on the safety, efficacy and improved quality-of-life for patients experiencing difficult-to-treat migraine. Post-hoc analyses were also evaluated in patients who may experience challenges when managing their migraine due to comorbidities. Migraine creates a significant disease and economic burden. With more than one billion people impacted globallyi, migraine is the second leading global cause of years lived with disabilityii and annual costs of the disease in the U.S. and EU are $200 billio
JEOL: Release of a New Schottky Field Emission Scanning Electron Microscope JSM-IT80025.5.2020 08:00:00 CEST | Press release
JEOL Ltd. (TOKYO:6951) (President & COO Izumi Oi) announces the release of a new Schottky field emission scanning electron microscope, JSM-IT800 in May 2020. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200524005002/en/ JSM-IT800 (Photo: Business Wire) Development Background Scanning electron microscopes (SEMs) are used in various fields, such as nanotechnology, metals, semiconductors, ceramics, medicine, and biology. As SEM applications are expanding from research and development to quality control and product inspection at manufacturing sites, SEM users are in need of faster high-quality data acquisition and simple compositional information confirmation with seamless operation. To meet these demands, the JSM-IT800, with the Intelligence Technology (IT) platform, incorporates our In-lens Schottky Plus field emission electron gun for high resolution imaging to fast elemental mapping, and an innovative electron optical cont
Ipsen: New Surveys Show Over 80% of Patients with Spasticity and Cervical Dystonia Treated with Botulinum Toxin-A Experience Debilitating Symptom Recurrence23.5.2020 07:00:00 CEST | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today presents the results of two patient surveys. The surveys involved over 400 respondents from five countries, living with spasticity or cervical dystonia and receiving botulinum neurotoxin type A (BoNT-A) injections. The results show that over 80% of respondents experienced debilitating symptom recurrence, and revealed that a lack of long-lasting symptom control between injections has a profound impact on the personal and professional lives of patients.1-4 “The results from these two important patient surveys provide significant insight into the real-life burden of the two conditions; however, they also highlight a worrying disconnect between patients’ treatment expectations and their actual experience. The findings, which build on our growing understanding of spasticity and cervical dystonia, provide us with the potential to unlock meaningful changes in clinical practice,” said Dr Alberto Esquenazi, Department of Physical Medicine
U.S. FDA Approves Takeda’s ALUNBRIG ® (brigatinib) as a First-Line Treatment Option for Patients Diagnosed with Rare and Serious Form of Lung Cancer22.5.2020 22:30:00 CEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) approved ALUNBRIG (brigatinib) for adult patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. This approval expands ALUNBRIG’s current indication to include the first-line setting. ALUNBRIG is a potent and selective next-generation tyrosine kinase inhibitor (TKI) designed to target ALK molecular alterations. “We’re extremely proud of the positive results ALUNBRIG has shown for newly diagnosed ALK+ NSCLC patients, particularly those with brain metastases,” said Teresa Bitetti, President, Global Oncology Business Unit, Takeda. “Through a robust clinical development program and ongoing investigations across the NSCLC treatment landscape, Takeda is committed to uncovering solutions for people living with devastating forms of lung cancer in need of new options. We believe this approva
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom